FindTrial
Sign In

Ceftobiprole medocaril

DRUG12 trials

Sponsors

Basilea Pharmaceutica, Centre Hospitalier Universitaire Dijon, Advanz Pharma

Conditions

Acute Bacterial Skin and Skin Structure InfectionsBacteremiaBacterial InfectionsCommunity-acquired Pneumonia (CAP)FeverGram-positive Bacterial InfectionsHepatic InsufficiencyHospital-acquired Pneumonia (HAP)

Phase 1

Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics
TerminatedNCT02527681
Basilea PharmaceuticaBacterial Infections
Start: 2016-11-22End: 2020-02-25Updated: 2023-06-05

Phase 2

Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus Aureus Bacteremia
WithdrawnNCT00505258
Basilea PharmaceuticaBacteremia
End: 2009-04-30Updated: 2013-02-20
Open and Exploratory Trial to Investigate the Pharmacokinetic of Ceftobiprole Medocaril in Patients With CSF Device
CompletedNCT03317093
Centre Hospitalier Universitaire DijonInflamed Meninges, Suspected Meningitis, Ventriculitis
Start: 2018-03-29End: 2019-11-04Updated: 2020-09-16

Phase 3

Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
CompletedNCT00210899
Basilea PharmaceuticaSkin Diseases, Bacterial, Skin Diseases, Infectious, Staphylococcal Skin Infections
Start: 2005-09-30End: 2006-10-31Updated: 2012-07-26
Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
CompletedNCT00228982
Basilea PharmaceuticaSkin Diseases, Bacterial, Skin Diseases, Infectious, Staphylococcal Skin Infections
Start: 2004-10-31End: 2005-12-31Updated: 2012-07-26
Ceftobiprole in the Treatment of Patients With Community-Acquired Pneumonia
CompletedNCT00326287
Basilea PharmaceuticaPneumonia
Start: 2006-06-30End: 2007-07-31Updated: 2012-08-02
A Study of Ceftobiprole in Patients With Fever and Neutropenia.
TerminatedNCT00529282
Basilea PharmaceuticaFever, Gram-positive Bacterial Infections, Neutropenia +1
Start: 2007-10-31End: 2008-01-31Updated: 2012-08-01
Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections
CompletedNCT03137173
Basilea PharmaceuticaAcute Bacterial Skin and Skin Structure Infections
Start: 2018-02-19End: 2019-04-22Updated: 2026-09-18
Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
CompletedNCT03138733
Basilea PharmaceuticaStaphylococcus Aureus Bacteremia
Start: 2018-08-26End: 2022-03-11Updated: 2023-11-08
Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia
CompletedNCT03439124
Basilea PharmaceuticaCommunity-acquired Pneumonia (CAP), Hospital-acquired Pneumonia (HAP)
Start: 2017-11-27End: 2020-03-16Updated: 2023-05-12
Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age
CompletedNCT05856227
Basilea PharmaceuticaNeonatal Sepsis
Start: 2023-08-06End: 2024-12-18Updated: 2025-07-28

Unknown Phase

Collection of Data of Ceftobiprole Treated Patients: Comparison of Patients With and Without Certain Diseases
CompletedNCT04170309
Advanz PharmaHepatic Insufficiency, Immunosuppression, Renal Insufficiency
Start: 2020-03-30End: 2023-06-09Updated: 2023-07-07

Related Papers

Safety of ceftobiprole in patients with impaired renal, hepatic or immune function: A multinational retrospective hospital chart review (RETRACE study).
2025-01-242 citations
2785. Characterization of Methicillin-resistant <i>Staphylococcus aureus</i> Bloodstream Isolates Recovered from Patients Enrolled in a Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole for Treatment of Bacteremia, Including Infective Endocarditis
Open Forum Infectious Diseases2023-11-27
1946. <i>In Vitro</i> Activity of Ceftobiprole against <i>Staphylococcus aureus</i> Bacteremia Isolates from the United States (2018–2020)
Open Forum Infectious Diseases2023-11-27
Ceftobiprole for Treatment of Complicated <i>Staphylococcus aureus</i> Bacteremia
New England Journal of Medicine2023-09-2786 citations
LB2302. Ceftobiprole Compared to Daptomycin With or Without Optional Aztreonam for the Treatment of Complicated <i>Staphylococcus aureus</i> (SAB): Results of a Phase 3, Randomized, Double-Blind Trial (ERADICATE)
Open Forum Infectious Diseases2022-12-013 citations
A <i>Post Hoc</i> Analysis of Two Phase III Trials Showing the Efficacy and Tolerability of Ceftobiprole in East Asian Patients
Future Microbiology2021-06-223 citations
Efficacy and Safety of Ceftobiprole in Patients Aged 65 years or Older: a <i>Post Hoc</i> Analysis of Three Phase III studies
Future Microbiology2021-05-018 citations
Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET)
Clinical Infectious Diseases2020-08-2161 citations
Ceftobiprole Versus Daptomycin in <i>Staphylococcus Aureus</i> Bacteremia: A Novel Protocol for a Double-Blind, Phase III trial
Future Microbiology2020-01-0131 citations
Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials.
2019-02-2617 citations
A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation.
2012-01-09106 citations